UNSPSC 51272005: Methohexital sodium

This classification denotes a barbiturate with the molecular formula C14H17N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60200PNZ7Q, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+-)-, monosodium salt but more generally known as methohexital sodium, which bears US NIH Compound Identifier 9391. European Medicines Agency schedules Methohexital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03223MIG.

Most nations, for tariff and trade purposes, schedule methohexital sodium under HS 29335400. As of Q4 2014, METHOHEXITAL SODIUM remains US FDA's Preferred Term for this commodity. Methohexital sodium bears US NLM identifiers UMLS ID C0304448 and NCI Concept Code C66117. SMILES: CCC#CC(C)C1(C(=O)[N-]C(=O)N(C1=O)C)CC=C.[NA+].

UNSPSC 51272005 Methohexital sodium is a Commodity code tracking a barbiturate anesthetic pharmaceutical product, yet the recent state and local contract opportunities tagged under this code show no procurement of methohexital itself. Instead, the opportunities reflect purchases of naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploratory vendor outreach for direct-to-manufacturer prescription programs. The code appears to be a catch-all pharmaceutical classification rather than a specific needle for methohexital procurement; state and local health agencies, including county health departments and state health and human services commissions, are using it to solicit pharmaceutical supplies broadly, not the anesthetic drug named in the code. The issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions).

Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response deadline July 26, 2023, though the posting date of June 30, 2026 appears inconsistent with the stated deadline), the Texas HHS Commission's RFI on Direct-to-Manufacturer Prescriptions program design (posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across multiple participating states (response deadline March 26, 2026). The code shows activity across Florida, Texas, and the upper Midwest through cooperative purchasing. Vendors pursuing opportunities under this code should expect to navigate pharmaceutical manufacturing and supply chain requirements including cGMP certification, Drug Supply Chain Security Act compliance, E-Verify verification, and substantial insurance coverage, with contracts structured on fixed-fee or net-pricing models over two-year initial terms.